AIM
JNP

Acrospire Investment Management’s Juniper Pharmaceuticals, Inc. Common Stock JNP Stock Holding History

Acrospire Investment Management’s Portfolio JNP Stock Details JNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-8,423
Closed -$43K – 1961
2017
Q2 		$43K Buy
8,423
+6,818
+425% +$30.5K 0.04% 1010
2017
Q1 		$8K Buy
+1,605
New +$8.11K 0.01% 1926

Other funds holding JNP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
MERSOM
Municipal Employees' Retirement System of Michigan Lansing, Michigan $8.81B AUM 10.88% 1-Year Est. Return
AG
Algert Global San Francisco, California $6.65B AUM 53.68% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acrospire Investment Management's JNP Position: Q3 2017 in Review

Acrospire Investment Management sold out of Juniper Pharmaceuticals, Inc. Common Stock (JNP) in Q3 2017, closing a stake of 8,423 shares — an estimated $43K sold.

Acrospire Investment Management first reported a position in JNP in Q1 2017 and held it in 2 quarters. The position peaked at $43K in Q2 2017. 31 funds tracked by Wall St. Rank hold JNP as of Q3 2017.

  • Acrospire Investment Management reported no remaining Juniper Pharmaceuticals, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 8,423 Juniper Pharmaceuticals, Inc. Common Stock shares in Q3 2017, an estimated $43K.
  • Acrospire Investment Management first reported a position in Juniper Pharmaceuticals, Inc. Common Stock in Q1 2017 and held it in 2 quarters.
  • Acrospire Investment Management's Juniper Pharmaceuticals, Inc. Common Stock position peaked at $43K in Q2 2017.
  • 31 funds tracked by Wall St. Rank held Juniper Pharmaceuticals, Inc. Common Stock as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.